Skip to main content

Table 1 Univariable and multivariable analyses for OS data

From: Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

  mOS HR univariable
(95% CI)
p-value HR multivariable (95% CI) p-value
Entire cohort (95% CI) 10.9 (7.8–14.0)      
Age ≤ 65 6.9      
Age > 65 13.2 0.57 (0.32–1.02) 0.062 0.50 (0.26–0.96) 0.039
Locally advanced 17.1      
Metastasized 9.4 1.62 (0.85–3.09) 0.114 1.45 (0.73–2.94) 0.287
ECOG PS 0 14.5      
ECOG PS 1–2 9.4 1.37 (0.76–2.48) 0.288 1.16 (0.63–2.17) 0.633
Ca19–9 ≤ mediana 11.0      
Ca19–9 > median 10.4 1.12 (0.61–2.07) 0.715   
Ca19–9 < 59xULN 11.3     
Ca19–9 ≥ 59xULN 6.8 1.59 (0.84–3.01) 0.187   
Albumin ≤37 g/L 8.3      
Albumin > 37 g/L 14.8 0.53 (0.30–0.95) 0.032 0.48 (0.26–0.90) 0.023
TPK grade 0 6.8      
TPK grade 1–4 14.7 0.29 (0.16–0.55) 0.001 0.54 (0.27–1.06) 0.073
Normal bilirubinb 11.3      
Elevated bilirubin 10.1 1.59 (0.56–4.51) 0.421   
Dose reduction 10.9      
Full dose 6.2 1.77 (0.90–3.51) 0.119 1.03 (0.50–2.13) 0.942
No 2nd line 8.2      
2nd line 12.0 0.80 (0.45–1.42) 0.429   
BM-tox grade 0–1 7.0      
BM-tox grade 2–4 14.5 0.46 (0.25–0.84) 0.017   
BM-tox grade 0–2 8.9      
BM-tox grade 3–4 not reachedc 0.41 (0.20–0.87) 0.012 0.58 (0.26–1.27) 0.172
No leucocytosisd 11.9      
Leucocytosis 8.2 1.41 (0.78–2.57) 0.272   
  1. Median OS in months. Abbreviations: HR Hazard ratio, CI Confidence interval, PS Performance status, TPK Platelet count, BM Bone marrow, LPK White blood cell count, ULN Upper limit of normal. aMedian CA19–9 was 567kU/l, bS-bil < 26 μmole/L at treatment start, c Due to censored cases (61%),d < 8.8 × 109/L at treatment start. Statistical significance at the 0.05 level marked in bold text.
\